News
MBRX
3.270
+9.36%
0.280
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 5d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 5d ago
Weekly Report: what happened at MBRX last week (0615-0619)?
Weekly Report · 6d ago
Weekly Report: what happened at MBRX last week (0608-0612)?
Weekly Report · 06/15 10:17
Weekly Report: what happened at MBRX last week (0601-0605)?
Weekly Report · 06/08 10:13
Moleculin Highlights Strong Market Interest in Annamycin AML Therapy
TipRanks · 06/05 13:01
Moleculin market research shows oncologists likely to prescribe Annamycin in relapsed/refractory AML
PUBT · 06/05 12:29
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
Barchart · 06/05 07:29
Moleculin Biotech Enrolls 45th Participant In Its Pivotal Phase 2B/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Relapsed Or Refractory Acute Myeloid Leukemia
Benzinga · 06/04 12:52
Moleculin enrolls 45th patient in Phase 2B/3 MIRACLE trial of Annamycin combo for relapsed AML
PUBT · 06/04 12:32
Weekly Report: what happened at MBRX last week (0525-0529)?
Weekly Report · 06/01 10:17
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO
TipRanks · 05/29 14:43
Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Was Presented At The American Society Of Clinical Oncology Annual Meeting
Benzinga · 05/29 12:26
Moleculin says pooled ASCO data show no detectable cardiotoxicity with Annamycin at high cumulative exposure
PUBT · 05/29 12:21
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Barchart · 05/29 07:21
Moleculin Biotech Releases Updated Investor Information Presentation
TipRanks · 05/26 12:40
Weekly Report: what happened at MBRX last week (0518-0522)?
Weekly Report · 05/25 10:20
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO
TipRanks · 05/22 21:14
Moleculin says ASCO accepts pooled cardiac safety analysis for Annamycin poster
PUBT · 05/21 21:02
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
Barchart · 05/21 16:02
More
Webull provides a variety of real-time MBRX stock news. You can receive the latest news about Moleculin Biotec through multiple platforms. This information may help you make smarter investment decisions.
About MBRX
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).